Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., . . . Flinn, I. W. (2018). First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget.

Byrd, John C., et al. "First-in-human Phase 1 Study of the BTK Inhibitor GDC-0853 in Relapsed or Refractory B-cell NHL and CLL." Oncotarget 2018.

Byrd, John C., et al. "First-in-human Phase 1 Study of the BTK Inhibitor GDC-0853 in Relapsed or Refractory B-cell NHL and CLL." Oncotarget 2018.